Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial.
By J. Dormandy, B. Charbonnel, D. Eckland, E. Erdmann, M. Massi-Benedetti, I. Moules, A. Skene, M. Tan, P. Lefèbvre, G. Murray and 20 more. The Lancet, 2005
4,141 citations recorded by the source corpus.
View Paper: https://www.semanticscholar.org/paper/195a434aa20efdeac2c7cc861bdae5d04ca6412f
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
- Juan José Marín-Peñalver
- C. Yancy
- T. Ivanova
- John B. Buse
- D. Nathan
- Silvio E. Inzucchi
- V. Basevi
- B. Bozkurt
Citations in the corpus
- Mining Electronic Health Records: A Survey (2017, methodology): “Dormandy et al. [Dormandy et al. 2005] used Kaplan-Meier estimates in their analysis of patients who were diagnosed with T2DM and were at high risk of data and non-fatal myocardial infarction and stroke.”
- Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy (2008, unknown): “On the other hand, the Prospective Pioglitazone Clinical Trial in macrovascular events (PROactive) demonstrated no significant effects of pioglitazone compared with placebo on the primary CVD outcome (a composite of all-cause mortality, non-fatal and silent myocardial infarction, stroke, major leg a”
- Cardiovascular actions of insulin. (2007, unknown): “cause mortality and nonfatal myocardial infarction (418).”
- Canadian Diabetes Association Clinical Practice Guidelines Expert Committee (2013, background): “Conversely, the evidence for pioglitazone suggests a possible reduced risk of cardiovascular events, although heart failure and increased fractures are still concerning side effects (35,36).”
- Update on the treatment of type 2 diabetes mellitus. (2016, background): “Thiazolidinediones : Although TZD do not increase the risk of hypoglycaemia, and pioglitazone may be beneficial in patients in secondary prevention [259] , the high cost and side effects that induce as weight gain, macular oedema, fluid retention, increased risk of heart failure and bone fractures,…”